Get the Stockscreener App
12.84
0.93%
-0.12
Uniqure N V stock is traded at $12.84, with a volume of 739.98K.
It is down -0.93% in the last 24 hours and down -13.88% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$12.96
Open:
$12.98
24h Volume:
739.98K
Relative Volume:
0.35
Market Cap:
$625.86M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-1.9815
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-9.45%
1M Performance:
-13.88%
6M Performance:
+82.65%
1Y Performance:
+105.11%
1-Day Range:
$12.53
$13.15
1-Week Range:
$12.53
$14.42
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
12.84 | 625.86M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - MarketBeat
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
(QURE) Proactive Strategies - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Price Down 6.7%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com - MarketBeat
abrdn plc Sells 419,726 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Swelling losses haven't held back gains for uniQure (NASDAQ:QURE) shareholders since they're up 147% over 1 year - Simply Wall St
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsuniQure (NASDAQ:QURE), CSL (OTC:CSLLY) - Benzinga
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - Quantisnow
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Analysts Set uniQure (NASDAQ:QURE) Price Target at $40.00 - MarketBeat
uniQure Announces Completion of Enrollment in the First - GlobeNewswire
UniQure Advances AMT-191 Trial in Fabry Disease -February 03, 2025 at 12:09 pm EST - Marketscreener.com
uniQure advances gene therapy trial for Fabry disease By Investing.com - Investing.com Australia
uniQure advances gene therapy trial for Fabry disease - Investing.com
Rare Disease Breakthrough: Gene Therapy Trial Shows Promise in Fabry Disease Treatment - StockTitan
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - The Manila Times
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Issues Negative Estimate for uniQure Earnings - MarketBeat
Analysts Set Expectations for uniQure FY2029 Earnings - MarketBeat
uniQure (NASDAQ:QURE) Trading Down 4.8%Should You Sell? - MarketBeat
uniQure Announces Favorable Recommendation from Independent - GlobeNewswire
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis - Marketscreener.com
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - The Manila Times
Game-Changing ALS Treatment: uniQure's Gene Therapy Hits Critical Milestone - StockTitan
FY2024 EPS Estimates for uniQure Reduced by HC Wainwright - Defense World
FY2029 Earnings Forecast for uniQure Issued By HC Wainwright - Defense World
HC Wainwright Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price - Defense World
H.C. Wainwright sets uniQure stock price target at $70 By Investing.com - Investing.com Australia
The Hidden Gem in Biotechnology? It’s Time to Take Notice - Jomfruland.net
Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? - Insider Monkey
H.C. Wainwright sets uniQure stock price target at $70 - Investing.com India
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
12 Most Promising Growth Stocks According to Wall Street Analysts - Insider Monkey
Assenagon Asset Management S.A. Sells 197,775 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Analysts Offer Predictions for uniQure FY2025 Earnings - Defense World
Brokers Offer Predictions for uniQure FY2025 Earnings - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Dec 09 '24 |
Sale |
7.55 |
1,796 |
13,560 |
166,713 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):